TransCode Therapeutics Analyst Ratings
TransCode Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2022 | 1068.22% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 06/07/2022 | 1847.04% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 11/15/2022 | 1068.22% | HC 溫賴特 & 有限公司. | 十美元 → 6 美元 | 維護 | 購買 |
| 06/07/2022 | 1847.04% | HC 溫賴特 & 有限公司. | → 10 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for TransCode Therapeutics (RNAZ)?
轉碼治療（RNAZ）的目標價格是多少？
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on November 15, 2022. The analyst firm set a price target for $6.00 expecting RNAZ to rise to within 12 months (a possible 1068.22% upside). 2 analyst firms have reported ratings in the last year.
韋萊特有限公司於 2022 年 11 月 15 日報導了轉碼治療（納斯達克代碼：RNAZ）的最新價格目標。該分析師公司設定了 6.00 美元的價格目標，預計 RNAZ 將在 12 個月內上升（可能是 1068.22％ 的上行空間）。2 家分析師公司在去年報告了評級。
What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?
轉碼治療（RNAZ）的最新分析師評級是什麼？
The latest analyst rating for TransCode Therapeutics (NASDAQ: RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics maintained their buy rating.
轉碼治療（納斯達克代碼：RNAZ）的最新分析師評級由 HC 溫賴特公司提供，而轉碼治療學保持其買入評級。
When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?
什麼時候將發布或更新轉碼治療（RNAZ）的下一個分析師評級？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
分析師在進行了廣泛的研究後獲得股票評級，其中包括通過公共財務報表，與 TransCode Theraptive 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。轉碼治療的最後一個評級於 2022 年 11 月 15 日提交，因此您應該期望下一個評分將在 2023 年 11 月 15 日左右的某個時候提供。
Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?
分析師評級轉碼治療（RNAZ）是否正確？
While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a maintained with a price target of $10.00 to $6.00. The current price TransCode Therapeutics (RNAZ) is trading at is $0.51, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的轉碼治療（RNAZ）評級維持，目標價格為 10.00 美元至 6.00 美元。當前價格轉碼治療（RNAZ）的交易價格為 0.51 美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。